参考文献/References:
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1):7-30. DOI:10.3322/caac.21387.
[2] Simsir A, Cal C, Mammadov R, et al. Biochemical recurrence after radical prostatectomy:is the disease or the surgeon to blame?[J]. Inter Braz J Urol, 2011, 37(3):328-335. DOI:10.1590/S1677-55382011000300006.
[3] Avril N, Dambha F, Murray I, et al. The clinical advances of fluo-rine-2-D-deoxyglucose-positron emission tomography/computed tomography in urological cancers[J]. Int J Urol, 2010, 17(6):501-511. DOI:10.1111/j.1442-2042.2010.02509.x.
[4] Lindenberg L, Choyke P, Dahut W. Prostate cancer imaging with novel PET tracers[J]. Curr Urol Rep, 2016, 17(3):18. DOI:10.1007/s11934-016-0575-5.
[5] Bauman G, Belhocine T, Kovacs M, et al. 18F-fluorocholine for prostate cancer imaging:a systematic review of the literature[J]. Prostate Cancer Prostatic Dis, 2012, 15(1):45-55. DOI:10.1038/pcan.2011.35.
[6] Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates[J]. Urol Oncol, 2013, 31(4):427-435.
[7] Roethke MC, Kuru TH, Afshar-Oromieh A, et al. Hybrid positron emission tomography-magnetic resonance imaging with Gallium 68 prostate-specific membrane antigen tracer:a next step for imaging of recurrent prostate cancer-preliminary results[J]. Eur Urol,2013, 64(5):862-864. DOI:10.1016/j.eururo.2013.08.003.
[8] Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2014, 41(1):11-20. DOI:10.1007/s00259-013-2525-5.
[9] Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2015, 42(2):197-209. DOI:10.1007/s00259-014-2949-6.
[10] Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy[J]. J Nucl Med, 2015, 56(5):668-674. DOI:10.2967/jnumed.115.154153.
[11] Eiber M, Weirich G, Holzapfel K, et al. 68Ga-PSMA HBED-CC PET/MRI in intermediate and high-risk prostate cancer improves the intraprostatic tumor localization compared to multiparametric Mr[J/OL]. J Nucl Med, 2016, 57(Suppl 2):28[2017-03-01]. http://jnm.snmjournals.org/content/57/supplement_2/28.short.
[12] Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer[J]. J Urol, 2016, 195(5):1436-1443. DOI:10.1016/j.juro.2015.12.025.
[13] Washburn LC, Sun TT, Byrd B, et al. 1-aminocyclobutane[11C]car-boxylic acid, a potential tumor-seeking agent[J]. J Nucl Med,1979, 20(10):1055-1061.
[14] Shoup TM, Goodman MM. Synthesis of[F-18]-1-amino-3-fluorocy-clobutane-1-carboxylic acid (FACBC):A PET tracer for tumor delineation[J]. J Labelled Comp Radiopharm, 1999, 42(3):215-225.DOI:10.1002/(SICI)1099-1344(199903)42:3<215:AID-JLCR180>3.0.CO;2-0.
[15] Okudaira H, Shikano N, Nishii R, et al. Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobu-tanecarboxylic acid in human prostate cancer[J]. J Nucl Med, 2011, 52(5):822-829. DOI:10.2967/jnumed.110.086074.
[16] Oka S, Hattori R, Kurosaki F, et al. A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer[J]. J Nucl Med, 2007, 48(1):46-55.
[17] Kairemo K, Rasulova N, Partanen K, et al. Preliminary clinical experience of trans-1-amino-3-(18)F-fluorocyclobutanecarboxylic acid (anti-(18) F-FACBC) PET/CT imaging in prostate cancer patients[J/OL]. Biomed Res Int, 2014:305182[2017-03-02]. https://www.hindawi.com/journals/bmri/2014/305182/. DOI:10.1155/2014/305182.
[18] Schuster DM, Taleghani PA, Nieh PT, et al. Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F]-fluorocyclobu-tane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake[J]. Am J Nucl Med Mol Imaging, 2013, 3(1):85-96.
[19] S?rensen J, Owenius R, Lax M, et al. Regional distribution and kinetics of[18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2013, 40(3):394-402. DOI:10.1007/s00259-012-2291-9.
[20] Turkbey B, Mena E, Shih J, et al. Localized prostate cancer detection with 18F FACBC PET/CT:comparison with Mr imaging and histopa-thologic analysis[J]. Radiology, 2014, 270(3):849-856. DOI:10.1148/radiol.13130240.
[21] Nanni C, Schiavina R, Boschi S, et al. Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse:preliminary results[J]. Eur J Nucl Med Mol Imaging, 2013, 40 Suppl 1:S11-17. DOI:10.1007/s00259-013-2373-3.
[22] McConathy J, Voll RJ, Yu W, et al. Improved synthesis of anti-[18F]FACBC:improved preparation of labeling precursor and automated radiosynthesis[J]. Appl Radiat Isot, 2003, 58(6):657-666.
[23] Chaly T, Dahl JR. Thin layer chromatographic detection of kryptofix 2.2.2 in the routine synthesis of[18F]2-fluoro-2-deoxy-D-glucose[J].Int J Rad Appl Instrum B, 1989, 16(4):385-387. DOI:10.1016/0883-2897(89)90105-0.
[24] Schuster DM, Votaw JR, Nieh PT, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma[J]. J Nucl Med, 2007, 48(1):56-63. DOI:10.1007/s00259-008-0993-9.
[25] Schuster DM, Savir-Baruch B, Nieh PT, et al. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT[J]. Radiology, 2011, 259(3):852-861. DOI:10.1148/radiol.11102023.
[26] Shuster JR, Lance RS, Troyer DA. Molecular preservation by extraction and fixation, mPREF:a method for small molecule biomarker analysis and histology on exactly the same tissue[J]. BMC Clin Pathol, 2011, 11(1):14. DOI:10.1186/1472-6890-11-14.
[27] Chillarón J, Estévez R, Mora C, et al. Obligatory amino acid exchange via systems bo,+-like and y+L-like. A tertiary active transport mechanism for renal reabsorption of cystine and dibasic amino acids[J]. J Biol Chem,1996, 271(30):17761-17770. DOI:10.1074/jbc.271.30.17761.
[28] Romeo E, Dave MH, Bacic D, et al. Luminal kidney and intestine SLC6 amino acid transporters of B0AT-cluster and their tissue distribution in Mus musculus[J]. Am J Physiol Renal Physiol, 2006, 290(2):F376-383. DOI:10.1152/ajprenal.00286.2005.
[29] Bodoy S, Martín L, Zorzano A, et al. Identification of LAT4, a novel amino acid transporter with system L activity[J]. J Biol Chem, 2005, 280(12):12002-12011. DOI:10.1074/jbc.M408638200.
[30] Park SY, Kim JK, Kim IJ, et al. Reabsorption of neutral amino acids mediated by amino acid transporter LAT2 and TAT1 in the basolateral membrane of proximal tubule[J]. Arch Pharm Res, 2005, 28(4):421-432. DOI:10.1007/BF02977671.
[31] Kanagawa M, Doi Y, Oka S, et al. Comparison of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid (anti-[18F]FACBC) accumulation in lymph node prostate cancer metastasis and lymphadenitis in rats[J]. Nucl Med Biol, 2014, 41(7):545-551. DOI:10.1016/j.nucmedbio.2014.04.004.
[32] Asano Y, Inoue Y, Ikeda Y, et al.Phase I clinical study of NMK36:a new PET tracer with the synthetic amino acid analogue anti-[18F]FACBC[J]. Ann Nucl Med, 2011, 25(6):414-418. DOI:10.1007/s12149-011-0477-z.
[33] Inoue Y, Asano Y, Satoh T, et al. Phase Ⅱa clinical trial of trans-1-amino-3-(18)F-fluoro-cyclobutane carboxylic acid in metastatic prostate cancer[J]. Asia Ocean J Nucl Medi Biol, 2014, 2(2):87-94.
[34] Nanni C, Schiavina R, Rubello D, et al. The detection of disease relapse after radical treatment for prostate cancer:is anti-3-18F-FACBC PET/CT a promising option?[J]. Nucl Med Commun, 2013, 34(9):831-833. DOI:10.1097/MNM.0b013e3283636eaf.
[35] Tolvanen T, Yli-Kerttula T, Ujula T, et al. Biodistribution and radiation dosimetry of[11C]choline:a comparison between rat and human data[J]. Eur J Nucl Med Mol Imaging, 2010, 37(5):874-883. DOI:10.1007/s00259-009-1346-z.
[36] Inoue Y, Asano Y, Satoh T, et al. Phase Ⅱa clinical trial of trans-1-amino-3-18F-fluoro-cyclobutane carboxylic acid in metastatic prostate cancer[J]. Asia Ocean J Nucl Medi Biol, 2014, 2(2):87-94.
[37] Ren J, Yuan L, Wen G, et al. The value of anti-1-amino-3-18F-fluo-rocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recur-rent prostate carcinoma:a meta-analysis[J]. Acta radiologica, 2015, 57(4):487-493. DOI:10.1177/0284185115581541.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[6]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[7]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[8]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[9]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[10]张巍,杨珂.18f正电子放射性药物生产及使用中医务人员的受照剂量研究[J].国际放射医学核医学杂志,2015,39(5):420.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 016]
zhang wei,yang ke..the research of radiation dose of 18f-fdg to pet/ct related personnel[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):420.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 016]
[11]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[12]廖光星,冷志欣,肖国有.前列腺癌骨转移影像诊断方法研究进展[J].国际放射医学核医学杂志,2016,40(6):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
Liao Guangxing,Leng Zhixin,Xiao Guoyou.Progress of imaging in the diagnosis of bone metastases of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
[13]徐慧琴,薛杨央,赵学峰,等.18F-FDG PET-CT诊断前列腺癌复发与转移的价值[J].国际放射医学核医学杂志,2011,35(2):81.[doi:10.3760/cma.j.issn.1673-4114.2011.02.004]
XU Hui-qin,XUE Yang-yang,ZHAO Xue-feng,et al.Value of 18F-FDG PET-CT in diagnoss of prostate cancer recurrence and metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):81.[doi:10.3760/cma.j.issn.1673-4114.2011.02.004]